DOPAR Drug Patent Profile
When do Dopar patents expire, and when can generic versions of Dopar launch?
Dopar is a drug marketed by Shire and is included in one NDA.
The generic ingredient in DOPAR is levodopa. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the levodopa profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DOPAR?
- What are the global sales for DOPAR?
- What is Average Wholesale Price for DOPAR?
Summary for DOPAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 3,893 |
| DailyMed Link: | DOPAR at DailyMed |
US Patents and Regulatory Information for DOPAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shire | DOPAR | levodopa | CAPSULE;ORAL | 016913-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shire | DOPAR | levodopa | TABLET;ORAL | 016913-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shire | DOPAR | levodopa | CAPSULE;ORAL | 016913-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shire | DOPAR | levodopa | CAPSULE;ORAL | 016913-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for DOPAR
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Acorda Therapeutics Ireland Limited | Inbrija | levodopa | EMEA/H/C/004786Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. | Authorised | no | no | no | 2019-09-19 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
